Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
1.
BMC Infect Dis ; 20(1): 469, 2020 Jul 02.
Artículo en Inglés | MEDLINE | ID: mdl-32615981

RESUMEN

BACKGROUND: Interferon-γ release assays (IGRA) with Resuscitation promoting factor (Rpf) proteins enhanced tuberculosis (TB) screening and diagnosis in adults but have not been evaluated in children. Children often develop paucibacillary TB and their immune response differs from that of adults, which together affect TB disease diagnostics and immunodiagnostics. We assessed the ability of Rpf to identify infection among household TB-exposed children in The Gambia and investigated their ability to discriminate Mycobacterium tuberculosis complex (MTBC) infection from active TB disease in children. METHODS: Detailed clinical investigations were done on 93 household TB-exposed Gambian children and a tuberculin skin test (TST) was administered to asymptomatic children. Venous blood was collected for overnight stimulation with ESAT-6/CFP-10-fusion protein (EC), purified protein derivative and RpfA, B, C, D and E. Interferon gamma (IFN-γ) production was measured by ELISA in supernatants and corrected for the background level. Infection status was defined by IGRA with EC and TB disease by mycobacterial confirmation and/or clinical diagnosis. We compared IFN-γ levels between infected and uninfected children and between infected and TB diseased children using a binomial logistic regression model while correcting for age and sex. A Receiver Operating Characteristics analysis was done to find the best cut-off for IFN-γ level and calculate sensitivity and specificity. RESULTS: Interferon gamma production was significantly higher in infected (IGRA+, n = 45) than in uninfected (IGRA-, n = 20) children after stimulation with RpfA, B, C, and D (P = 0.03; 0.007; 0.03 and 0.003, respectively). Using RpfB and D-specific IFN-γ cut-offs (33.9 pg/mL and 67.0 pg/mL), infection was classified with a sensitivity-specificity combination of 73-92% and 77-72% respectively, which was similar to and better than 65-75% for TST. Moreover, IFN-γ production was higher in infected than in TB diseased children (n = 28, 5 bacteriologically confirmed, 23 clinically diagnosed), following RpfB and D stimulation (P = 0.02 and 0.03, respectively). CONCLUSION: RpfB and RpfD show promising results for childhood MTBC infection screening, and both performed similar to and better than the TST in our study population. Additionally, both antigens appear to discriminate between infection and disease in children and thus warrant further investigation as screening and diagnostic antigens for childhood TB.


Asunto(s)
Antígenos Bacterianos/inmunología , Proteínas Bacterianas/inmunología , Citocinas/inmunología , Ensayos de Liberación de Interferón gamma/métodos , Tuberculosis Latente/diagnóstico , Tuberculosis Latente/epidemiología , Tamizaje Masivo/métodos , Mycobacterium tuberculosis/inmunología , Niño , Preescolar , Ensayo de Inmunoadsorción Enzimática , Composición Familiar , Femenino , Gambia/epidemiología , Humanos , Interferón gamma/inmunología , Interferón gamma/metabolismo , Tuberculosis Latente/microbiología , Masculino , Sensibilidad y Especificidad , Prueba de Tuberculina
2.
Int J Tuberc Lung Dis ; 21(7): 774-777, 2017 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-28633701

RESUMEN

The World Health Organization European Region has one of the highest rates of multidrug-resistant tuberculosis (MDR-TB) in the world, resulting in many vulnerable children being exposed each year. Evidence for preventive therapy following MDR-TB exposure is limited and current guidance is conflicting. An internet-based survey was performed to determine clinical practice in this region. Seventy-two clinicians from 25 countries participated. Practices related to screening and decision-making were highly variable. Just over half provided preventive therapy for children exposed to MDR-TB; the only characteristic associated with provision was practice within the European Union (adjusted OR 4.07, 95%CI 1.33-12.5).


Asunto(s)
Antituberculosos/administración & dosificación , Trazado de Contacto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Tuberculosis Resistente a Múltiples Medicamentos/prevención & control , Antituberculosos/farmacología , Niño , Toma de Decisiones , Europa (Continente) , Unión Europea , Encuestas de Atención de la Salud , Humanos , Internet , Tamizaje Masivo/métodos , Proyectos Piloto , Tuberculosis Resistente a Múltiples Medicamentos/diagnóstico , Tuberculosis Resistente a Múltiples Medicamentos/epidemiología , Organización Mundial de la Salud
3.
Clin Exp Immunol ; 181(1): 110-7, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25737039

RESUMEN

Antiretroviral therapy (ART) only partially restores HIV-induced alterations in lymphocyte populations. We assessed B and T cell phenotypes in a cohort of children from a single centre in the United Kingdom with perinatally acquired HIV compared to healthy controls. The majority of HIV infected children (44 of 56) were on fully suppressive combination ART. Children with perinatally acquired HIV had significantly lower memory B and CD4(+) CD45RO(+) CXCR5(+) [follicular T helper cell (Tfh)-like] T cell percentages. Detectable viraemia was associated with higher CD21(-) (activated and exhausted/tissue-like memory) B cells. A greater proportion of life spent on suppressive ART was associated with higher memory B cell percentages. These results suggest that early and sustained suppressive ART may preserve B and T cell phenotypes in perinatally acquired HIV and limit deficits in humoral immunity. A lower proportion of circulating Tfh-like cells in HIV infected children appears to be independent of HIV treatment history and ongoing HIV viraemia and warrants further investigation.


Asunto(s)
Subgrupos de Linfocitos B/inmunología , Infecciones por VIH/inmunología , Memoria Inmunológica/inmunología , Receptores CXCR5/metabolismo , Linfocitos T Colaboradores-Inductores/inmunología , Adolescente , Antirretrovirales/uso terapéutico , Subgrupos de Linfocitos B/virología , Niño , Preescolar , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Lactante , Masculino , Receptores de Complemento 3d/inmunología , Linfocitos T Colaboradores-Inductores/virología
4.
Eur Respir J ; 36(5): 1185-206, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20530046

RESUMEN

Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Individuals who are treated with TNF antagonists are at an increased risk of reactivating latent infections, especially tuberculosis (TB). Following TNF antagonist therapy, the relative risk for TB is increased up to 25 times, depending on the clinical setting and the TNF antagonist used. Interferon-γ release assays or, as an alternative in individuals without a history of bacille Calmette-Guérin vaccination, tuberculin skin testing is recommended to screen all adult candidates for TNF antagonist treatment for the presence of latent infection with Mycobacterium tuberculosis. Moreover, paediatric practice suggests concomitant use of both the tuberculin skin test and an interferon-γ release assay, as there are insufficient data in children to recommend one test over the other. Consequently, targeted preventive chemotherapy is highly recommended for all individuals with persistent M. tuberculosis-specific immune responses undergoing TNF antagonist therapy as it significantly reduces the risk of progression to TB. This TBNET consensus statement summarises current knowledge and expert opinions and provides evidence-based recommendations to reduce the TB risk among candidates for TNF antagonist therapy.


Asunto(s)
Anticuerpos Monoclonales/efectos adversos , Mycobacterium tuberculosis/inmunología , Tuberculosis Pulmonar/epidemiología , Tuberculosis Pulmonar/inmunología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Antiinflamatorios/efectos adversos , Antirreumáticos/efectos adversos , Humanos , Huésped Inmunocomprometido , Factores de Riesgo
5.
Eur Respir J ; 33(5): 956-73, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19407047

RESUMEN

Tuberculosis control relies on the identification and preventive treatment of individuals who are latently infected with Mycobacterium tuberculosis. However, direct identification of latent tuberculosis infection is not possible. The diagnostic tests used to identify individuals latently infected with M. tuberculosis, the in vivo tuberculin skin test and the ex vivo interferon-gamma release assays (IGRAs), are designed to identify an adaptive immune response against, but not necessarily a latent infection with, M. tuberculosis. The proportion of individuals who truly remain infected with M. tuberculosis after tuberculin skin test or IGRA conversion is unknown. It is also uncertain how long adaptive immune responses towards mycobacterial antigens persist in the absence of live mycobacteria. Clinical management and public healthcare policies for preventive chemotherapy against tuberculosis could be improved, if we were to gain a better understanding on M. tuberculosis latency and reactivation. This statement by the TBNET summarises knowledge and limitations of the currently available tests used in adults and children for the diagnosis of latent tuberculosis infection. In summary, the main issue regarding testing is to restrict it to those who are known to be at higher risk of developing tuberculosis and who are willing to accept preventive chemotherapy.


Asunto(s)
Pruebas Inmunológicas/métodos , Mycobacterium tuberculosis/inmunología , Selección de Paciente , Tuberculosis/diagnóstico , Tuberculosis/inmunología , Antígenos Bacterianos , Antituberculosos/farmacología , Trazado de Contacto , Medicina Basada en la Evidencia , Humanos , Tamizaje Masivo/métodos , Técnicas de Diagnóstico Molecular , Valor Predictivo de las Pruebas , Prueba de Tuberculina , Tuberculosis/tratamiento farmacológico , Tuberculosis/transmisión
6.
Br J Haematol ; 130(4): 595-603, 2005 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16098075

RESUMEN

Adenovirus (AdV) infections are a frequent cause of morbidity and mortality following allogeneic stem cell transplantation (SCT), and disseminated infection is associated with high mortality, particularly in paediatric SCT. Here, we describe an approach to reduce mortality from adenoviraemia by combining prospective monitoring for the occurrence of adenoviraemia using a sensitive polymerase chain reaction method, early antiviral therapy and prompt withdrawal of immunosuppression. A total of 155 consecutive paediatric SCT procedures were prospectively monitored, of which 113 (73%) transplants involved donors other than matched siblings and 126 (83%) employed T-cell depletion. Adenoviraemia was detected in 26/155 (17%) transplants and developed exclusively in patients who had received T-cell-depleted grafts. Withdrawal of immunosuppression coupled with early antiviral therapy led to resolution of adenoviraemia in 19/26 (81%) patients with only five patients succumbing to disseminate AdV infection. Survival from adenoviraemia was associated with lymphocyte recovery to above 0.3x10(9)/l. Mortality was closely linked with the absence of lymphocyte recovery because of profound T-cell depletion of the graft with CD34+ magnetic-activated cell sorting. Mortality from disseminated AdV infection was 5/26 (19%) in this study, which is significantly lower than previously reported.


Asunto(s)
Infecciones por Adenoviridae/complicaciones , Adenoviridae , Enfermedades Hematológicas/cirugía , Trasplante de Células Madre/efectos adversos , Adenoviridae/genética , Adolescente , Antivirales/uso terapéutico , Niño , Preescolar , ADN Viral/análisis , ADN Viral/sangre , Heces/virología , Ganciclovir/uso terapéutico , Enfermedades Hematológicas/virología , Humanos , Inmunosupresores/uso terapéutico , Lactante , Modelos Logísticos , Nasofaringe/virología , Nariz/virología , Reacción en Cadena de la Polimerasa/métodos , Pronóstico , Estudios Prospectivos , Factores de Riesgo , Acondicionamiento Pretrasplante/métodos , Trasplante Homólogo , Resultado del Tratamiento
7.
Int Arch Occup Environ Health ; 75(3): 153-62, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-11954982

RESUMEN

OBJECTIVE: To co-ordinate the work of the main European research teams in the field of thermal factors in order to develop and improve significantly the methods presently available for assessing the risks of heat disorders encountered during work in hot conditions. METHOD: Each item from the required sweat rate model was reviewed on the basis of the most recent literature. A database with 1,113 laboratory and field experiments, covering the whole range of hot working conditions, was assembled and used for the validation. RESULTS: Influence of clothing ensemble on heat exchange: methods and formulas were developed that take into account the dynamic effects associated with forced convection and the pumping effect associated with body movements and exercise. Prediction of the average skin temperature: the model used in the required sweat rate standard ISO 7933 was extended to cover more severe conditions with high radiation and high humidity and different clothing and take into account the rectal temperature for the prediction of the skin temperature. Criteria for estimating acceptable exposure times in hot work environments: criteria were reviewed and updated concerning the maximum increase in core temperature and the acceptable water loss, for acclimatised and nonacclimatised subjects. These limits are intended to protect 95% of the population. Measuring strategy: a strategy was developed to assess the risks in any working situation with varying conditions of climate, metabolic rate or clothing. A detailed methodology was developed in three stages: an "observation" method for the recognition of the conditions that might lead to thermal stress; an "analysis" method for evaluating the problem and optimising the solutions; and an "expert" method for in-depth analysis of the working situation when needed. VALIDATION: the different results were used to prepare a revision of the interpretation procedure proposed in the ISO standard 7933. We validated the modified approaches using the database. This involved the whole range of conditions for which the model was extended, namely conditions with high and low radiation, humidity and air velocity as well as fluctuating conditions. Based on these results, the predicted heat strain model was developed: it is presently proposed as an ISO and CEN standard.


Asunto(s)
Trastornos de Estrés por Calor/fisiopatología , Exposición Profesional/análisis , Medición de Riesgo/métodos , Lugar de Trabajo , Fenómenos Biomecánicos , Vestuario , Europa (Continente)/epidemiología , Trastornos de Estrés por Calor/epidemiología , Trastornos de Estrés por Calor/etiología , Trastornos de Estrés por Calor/prevención & control , Humanos , Temperatura Cutánea , Sudoración
8.
J Infect Dis ; 182(3): 895-901, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10950786

RESUMEN

A novel in vitro whole blood model was developed to study human antimycobacterial immunity. Recombinant reporter mycobacteria were used to enumerate the bacteria, and interactions between host immune cells and mycobacteria were studied using whole blood rather than cell fractions. The ability of healthy tuberculin-positive and tuberculin-negative individuals to restrict mycobacterial growth was compared. Growth of luminescent mycobacteria was significantly lower in blood samples of tuberculin-positive individuals than in blood samples of tuberculin-negative individuals (P=.005). Restricted mycobacterial growth was associated with significantly higher production of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma (P=.01 and.004, respectively). Inhibition of the TNF-alpha and IFN-gamma response pathways by neutralizing monoclonal antibodies increased mycobacterial growth in whole blood. This model is the first functional assay in which individual variations in cell-mediated immunity are shown to correlate with differences in ability to control mycobacterial growth. It provides a new tool for studying human mycobactericidal mechanisms and, potentially, for the evaluation of improved vaccines.


Asunto(s)
ADN Recombinante/inmunología , Genes Reporteros , Mycobacterium/genética , Mycobacterium/inmunología , Adulto , Anticuerpos Monoclonales , Formación de Anticuerpos , Humanos , Inmunidad Celular , Técnicas In Vitro , Interferón gamma/biosíntesis , Interferón gamma/inmunología , Interleucina-12/inmunología , Mycobacterium bovis/crecimiento & desarrollo , Prueba de Tuberculina , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/inmunología
9.
Arch Dis Child ; 74(5): 455-7, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8669966

RESUMEN

AIDS related Kaposi's sarcoma is commonly seen in homosexual men, only occasionally in men and women with heterosexually acquired HIV, and extremely rarely in children. The case of an HIV infected mother and her vertically infected child who both developed visceral Kaposi's sarcoma is reported. It is proposed that the putative Kaposi's sarcoma agent may also be transmitted vertically.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/transmisión , Transmisión Vertical de Enfermedad Infecciosa , Sarcoma de Kaposi/etiología , Síndrome de Inmunodeficiencia Adquirida/complicaciones , Adulto , Preescolar , Femenino , Humanos , Masculino
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA